Results 21 to 30 of about 76,618 (225)
Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. [PDF]
PLoS ONE, 2013 Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery ...
Katsuyuki Iwatsuki +7 more
doaj +1 more source
Arthritis Research & Therapy, 2020 Background At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into ...
Giulia Armaroli +12 more
doaj +1 more source
Scientific Reports, 2022 We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi +11 more
doaj +1 more source
Viewpoint on handling anti-TNF failure in psoriasis [PDF]
, 2013 An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core +1 more source
Immunity, Inflammation and Disease, 2022 Introduction This study aimed to investigate the effect of etanercept in psoriasis and its underlying mechanism. Methods Female mice were treated with imiquimod (IMQ) to induce psoriasis, and intraperitoneally administered etanercept (0.1–0.4 mg/ml). The
Xiaoqing Li +3 more
doaj +1 more source
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]
, 2019 Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro +5 more
core +3 more sources
Adverse reactions of biological therapies in patients with psoriasis [PDF]
, 2017 Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.
Georgescu, Simona R. +5 more
core +8 more sources
Pediatric Rheumatology Online Journal, 2009 Background Temporomandibular joint (TMJ) arthritis in children causes alterations in craniomandibular growth. This abnormal growth may be prevented by an early anti-inflammatory intervention.
Nyengaard Jens R +6 more
doaj +1 more source
Effect of Etanercept on anti-carbamylated protein antibodies in patients with rheumatoid arthritis [PDF]
, 2015 Rheumatoid Arthritis (RA) is a systemic, chronic inflammatory disease characterized by inflammation of synovial joints and production of autoantibodies such as Rheumatoid Factor and antibodies directed against modified proteins - i.e.
Alessandri, Cristiano +4 more
core +1 more source
Clinical and functional characterisation of a novel TNFRSF1A c.605T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. [PDF]
, 2008 Objectives: To study the clinical outcome, treatment response, T-cell subsets and functional consequences of a novel tumour necrosis factor (TNF) receptor type 1 (TNFRSF1A) mutation affecting the receptor cleavage site.
B H Belohradsky +7 more
core +1 more source